Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
NANJING, China, March 1 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group , a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2009, on Tuesday, March 16, 2010, before the market opens in the United States. Simcere's Chief Executive Officer, Jinsheng Ren, and Chief Financial Officer, Frank Zhigang Zhao, will host an earnings conference call on the same day, at 8 a.m. ET (Tuesday, March 16, at 8 p.m. Beijing/Hong Kong time).
Please ask to be connected to Q4 2009 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 65611658.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .
The passcode for replay participants is: 88577131. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
CONTACT: Investor and Media Contacts, ir@simcere.com; In Nanjing, Frank
Zhao, Chief Financial Officer of Simcere Pharmaceutical Group,
+86-25-8556-6666 x8818; in Beijing, Ruirui Jiang of Brunswick Group,
+86-10-6566-2256; in the United States, Kate Tellier of Brunswick Group,
+1-212-333-3810; in Hong Kong, Joseph Lo Chi-Lun of Brunswick Group,
+852-3512-5000, all for Simcere Pharmaceutical Group
Web site: http://www.simcere.com/